Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial
暂无分享,去创建一个
F. Levin | S. Comer | F. Yocca | Jermaine D. Jones | Jermaine D Jones | R. Risinger | L. Rajachandran | Michael De Vivo | Jeff Sabados